The rheumatoid arthritis (RA) market has historically had many ‘disruptive’ events (new products and classes, indications extensions, biosimilar launches and new formulations) influencing pricing. The objective for this project was to take learnings from these historical events and apply to an auto-immune condition to predict future price changes in EU5 and the US. An RA price evolution was conducted for EU5 and the US, highlighting key disruptive events and subsequent impact on price. A ‘matching exercise’ between those in the auto-immune space and analogous RA products allowed formation of price projections in each market. In the US, ∼5% annual list price inflation is expected, with pricing dynamics occurring at the net price level. LoE events or biosimilar introduction in the near term (the next 5-7 years) is not expected to significantly impact net price. Although net price is expected to decline with time on the market and class crowding (∼30% reductions seen with anti-TNFs). Conversely, in European markets, disruptive events are expected to change list pricing dynamics. In France especially, a cross-therapy price convergence is expected, catalysed by biosimilar introduction and LoE events. Originator list price erosions may be as high as 40% in 5 years (seen post-biosimilar launch). Dissociation from biosimilar benchmarks may be possible for new launches by targeting sub-groups with a greater unmet need (with 5-15% price premiums seen in RA), and may have a lower long-term list price erosion. In Germany, list prices are expected to remain stable over time unless a biosimilar launch reaches ∼20% market share, causing a formation of reference price group with the originator; then list price drops are expected. The auto-immune space is set to become more competitive, with products across EU5 and the US providing discounts to remain competitive